Share on LinkedInShare on LinkedIn

ARTICLE · 06 JANUARY 2011

Federal Circuit Law Governs Patent Assignment Interpretation and Nunc Pro Tunc Assignments Cannot Retroactively Confer Standing

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Abraxis Bioscience, Inc. v. Navinta LLC, No. 09-1539 (Fed. Cir. Nov. 9, 2010), the Federal Circuit reversed the district court’s denial of Navinta LLC’s ("Navinta") motion to dismiss for lack of standing, vacated the judgment, and remanded for the district court to dismiss the complaint with prejudice.

United StatesIntellectual Property

Last Month at the Federal Circuit - December 2010

Judges: Newman (dissenting), Gajarsa (author), and Linn
[Appealed from D.N.J., Judge Pisano]

In Abraxis Bioscience, Inc. v. Navinta LLC, No. 09-1539 (Fed. Cir. Nov. 9, 2010), the Federal Circuit reversed the district court's denial of Navinta LLC's ("Navinta") motion to dismiss for lack of standing, vacated the judgment, and remanded for the district court to dismiss the complaint with prejudice.

Abraxis Bioscience, Inc. ("Abraxis") markets the anesthetic Naropin®. U.S. Patent No. 4,870,086 ("the '086 patent") discloses Naropin's active ingredient, ropivacaine hydrochloride monohydrate ("ropivacaine"). U.S. Patent Nos. 5,670,524 ("the '524 patent") and 5,834,489 ("the '489 patent") disclose methods of pain treatment using low-concentration ropivacaine.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from